Navigation Links
U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
Date:4/8/2008

- ORENCIA is a First-in-Class Biologic Treatment Option Now Available for

Use in Pediatric Patients with JIA(1,2) -

PRINCETON, N.J., April 8, 2008 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved ORENCIA(R) (abatacept) for reducing signs and symptoms in pediatric patients six years and older with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA). ORENCIA may be used as monotherapy or concomitantly with methotrexate (MTX). ORENCIA should not be administered concomitantly with tumor necrosis factor (TNF) antagonists and is not recommended for use concomitantly with other biologic rheumatoid arthritis (RA) therapy, such as anakinra. This new indication for ORENCIA provides significant evidence of its durable efficacy and long-term safety in pediatric patients, including those initiating biologic therapy for the first time. The safety and efficacy of ORENCIA in JIA were assessed in a three-part study through one year. The approval of ORENCIA in JIA represents the ongoing commitment of Bristol-Myers Squibb in this therapeutic area.

"In a JIA clinical trial, ORENCIA provided meaningful and sustained improvements in this patient population across three major sub-types of JIA through one year," said Edward H. Giannini, M.Sc., Dr.P.H., Professor of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, OH.

The approval is based on the AWAKEN (Abatacept Withdrawal study to Assess efficacy and safety in Key Endpoints in juvenile idiopathic arthritis Not responding to current treatment) trial, which evaluated the efficacy and safety of ORENCIA(R) (abatacept) in
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
2. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
3. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
4. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
5. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
6. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
7. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
8. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
9. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
10. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
11. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... , May 19, 2013  The non-surgical ... temperature radiofrequency (RF) energy is effective in control ... reduces the need for medication 10 years post-procedure, ... today at the Digestive Disease Week (DDW) meeting ... . "The sustained improvement ...
(Date:5/18/2013)... NEW YORK , May 18, 2013 /PRNewswire/ ... securities law firm, is investigating potential securities fraud ... (NASDAQ: AVEO). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ... the Company and its executives violated federal securities ... regarding the Company,s Phase III drug trials for ...
(Date:5/17/2013)... , May 17, 2013  Lakeland Industries, Inc. (NASDAQ: ... protective clothing for industry, healthcare and to first responders ... its financial results for the fiscal 2013 fourth quarter ... 21, 2013 at stock market close and will conduct ... p.m. eastern. (Logo: http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ) ...
Breaking Medicine Technology:Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 2Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 3Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2
...  theVisualMD, www.thevisualmd.com , the world,s leading health visualization resource ... Visual Rules of Wellness. Quest Diagnostics (NYSE: DGX ... services, is the official sponsor of the initiative,s first rule ... of Wellness aim to bring readers a new understanding of ...
... 3, 2012   GP Strategies Corporation (NYSE: ... of sales and technical training, e-Learning solutions, management consulting ... L.P. ("Sagard Capital") has agreed to purchase 350,000 shares ... The closing of the transaction is subject to customary ...
Cached Medicine Technology:theVisualMD Launches a Revolutionary New Visual Path to Wellness 2theVisualMD Launches a Revolutionary New Visual Path to Wellness 3theVisualMD Launches a Revolutionary New Visual Path to Wellness 4Sagard Capital Increases Ownership in GP Strategies by 350,000 Shares in a Private Transaction with Bedford Oak Partners, L.P. 2Sagard Capital Increases Ownership in GP Strategies by 350,000 Shares in a Private Transaction with Bedford Oak Partners, L.P. 3
(Date:5/20/2013)... WEDI, the leading authority on the ... healthcare information, announced today at the WEDI 22nd Annual ... State Collaborative Initiative. The new initiative will bring together ... increase efficiencies and reduce the significant time and costs ... new initiative is to help facilitate inter-state communication around ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 VHA ... the leader in automated, provider-led population health improvement, ... to effect change and successfully pursue population health ... services and technology to accelerate the transition to ... VHA IMPERATIVTM performance improvement suite of services, the ...
(Date:5/20/2013)... The Multiple System Atrophy Coalition (formerly the SDS/MSA ... Multiple System Atrophy (MSA) Research Grant Program . ... grass roots fundraising has grown and enabled the 501(c)3 ... now include education, advocacy and research funding initiatives. ... Coalition go directly into a dedicated MSA Research Fund, ...
(Date:5/20/2013)... Online education provides the convenience, flexibility and cost-saving ... According to the American Heart Association, 27% of ... to eLearning due to changing economic conditions. The ... budgets, but it is also proven to enhance ... higher retention of content is probable, given the ...
(Date:5/20/2013)... The 17th ECCO 38th ESMO 32nd ESTRO ... Amsterdam, The Netherlands ( http://www.rai.nl ), from Friday 17 ... fide journalists is free. , The congress will build ... Organisation), ESMO (European Society for Medical Oncology) and ESTRO ... is the only cancer congress in Europe to offer ...
Breaking Medicine News(10 mins):Health News:WEDI Launches New ICD-10 State Collaborative Initiative to Increase Efficiencies and Reduce Compliance Time and Costs 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 3Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 4Health News:Multiple System Atrophy (MSA) Research Grant Program Announced 2Health News:Multiple System Atrophy (MSA) Research Grant Program Announced 3Health News:Multiple System Atrophy (MSA) Research Grant Program Announced 4Health News:Multiple System Atrophy (MSA) Research Grant Program Announced 5Health News:Swank HealthCare Announces New Offering of Additional American Heart Association’s Accredited Online Courses 2Health News:Media registration for the European Cancer Congress 2
... Rochelle, NY -- The current issue of Medical ... Liebert, Inc., explores how the U.S. military is incorporating ... military personnel serving in the war zones and the ... issue is available online at http://www.liebertpub.com/acu . ...
... 4, 2012 As the pharmaceutical industry continues to ... protecting patients from counterfeit medicines, as well as the ... mounted. In an effort to encourage comprehensive public standards ... is proposing a set of recommended best practices that ...
... used extensively in Chinese traditional medicine that kill ... the leading causes of tooth loss in children and adults. ... , they say that these substances could have a role ... Stefan Gafner and colleagues explain that the dried root ...
... Weight loss surgery is not a cure for type 2 ... a new study published in the British Journal of ... to 80 per cent of diabetes patients have been cured ... that only 41 per cent of patients achieve remission using ...
... -- Arrogant people are less likely than humble people to ... Although personal factors (such as previous time commitments and ... how many people are watching) come into play, humility is ... helping hand, according to the study published online Jan. 2 ...
... a study that investigates the challenges of disseminating clinical research ... have found that fewer than half of a sample of ... Health (NIH) were published within 30 months of completing the ... issue of the British Medical Journal , which focuses ...
Cached Medicine News:Health News:Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity 2Health News:Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity 3Health News:Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity 4Health News:Scientists reassess weight loss surgery for type 2 diabetes 2Health News:Need Help? Seek Out the Humble 2Health News:Many NIH-funded clinical trials go unpublished over 2 years after completion 2
... is an automated microplate analyzer ... microplate techniques. Open architecture design ... many manufacturers' microplate assays and ... R.I.A. and I.F.A. methods as ...
... MAP D-Type can combine a number ... 180 microplates on a simple to ... instrument is a multifunctional stand-alone device ... larger robotic systems. Custom and standard ...
... provides a fast, accurate assessment of,patient ... patented,state-of-the-art optics yield accurate measurements of ... total hemoglobin. When,used in combination with ... gives a comprehensive and complete assessment ...
The Stat Profile pHOx CO-Oximeter is intended for use in those situations where a more comprehensive profile beyond the measured hematocrit, hemoglobin, and SO2% offered by the Stat Profile pHOx ...
Medicine Products: